Rising Prevalence of Low-Frequency PPM1D Gene Mutations after Second HDCT in Multiple Myeloma
Open Access
- 29 July 2024
- journal article
- research article
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 46 (8) , 8197-8208
Abstract
Multiple myeloma (MM) first-line treatment algorithms include immuno-chemotherapy (ICT) induction, high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) consolidation, followed by lenalidomide maintenance. After these initial therapies, most patients suffer a disease relapse and require subsequent treatment lines including ICT, additional HDCT and ASCT, or novel immunotherapies. The presence of somatic mutations in peripheral blood cells has been associated with adverse outcomes in a variety of hematological malignancies. Nonsense and frameshift mutations in the PPM1D gene, a frequent driver alteration in clonal hematopoiesis (CH), lead to the gain-of-function of Wip1 phosphatase, which may impair the p53-dependent G1 checkpoint and promote cell proliferation. Here, we determined the presence of PPM1D gene mutations in peripheral blood cells of 75 subsequent myeloma patients in remission after first or second HDCT/ASCT. The prevalence of truncating PPM1D gene mutations emerged at 1.3% after first HDCT/ASCT, and 7.3% after second HDCT/ASCT, with variant allele frequencies (VAF) of 0.01 to 0.05. Clinical outcomes were inferior in the PPM1D-mutated (PPM1Dmut) subset with median progression-free survival (PFS) of 15 vs. 37 months (p = 0.0002) and median overall survival (OS) of 36 vs. 156 months (p = 0.001) for the PPM1Dmut and PPM1Dwt population, respectively. Our data suggest that the occurrence of PPM1D gene mutations in peripheral blood cells correlates with inferior outcomes after ASCT in patients with multiple myeloma.Keywords
This publication has 30 references indexed in Scilit:
- Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic riskBlood Cancer Journal, 2024
- Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic reviewBlood Cancer Journal, 2024
- Clinical significance of clonal hematopoiesis in the setting of autologous stem cell transplantation for lymphomaAmerican Journal of Hematology, 2022
- Long‐term safety of the stem cell releasing compound plerixafor for peripheral stem cell collection in myeloma patientsHematological Oncology, 2022
- Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trialBone Marrow Transplantation, 2022
- The mutagenic impact of melphalan in multiple myelomaLeukemia, 2021
- Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplantNature Communications, 2020
- Navigating the treatment landscape in multiple myeloma: which combinations to use and when?Annals of Hematology, 2018
- Short overview on the current standard of treatment in newly diagnosed multiple myelomamemo - Magazine of European Medical Oncology, 2018
- Treatment of multiple myelomaNature Reviews Clinical Oncology, 2011